Xyntha®, Xyntha Solofuse® (antihemophilic factor [recombinant]) – New indication
August 13, 2020 - The FDA approved Wyeth’s Xyntha (antihemophilic factor [recombinant]) and Xyntha Solofuse (antihemophilic factor [recombinant]) for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes.
Top